MaxCyte, Inc. Grant of Options and PDMR Dealing (2646G)
March 28 2022 - 8:19AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2646G
MaxCyte, Inc.
28 March 2022
The following amendments have been made to the Grant of Options
and PDMR Dealing announcement released on 28 March 2022 at 07:00
under RNS number 1548G.
An incorrect Identification Code in section 4.b has been
removed.
Section 4.c, Nature of the transaction, has been amended to
"Grant of Options" instead of "Exercise of options and Sale of
Common Stock by PDMR".
All other details remain unchanged.
The full amended text is shown below.
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options and PDMR Dealing
Gaithersburg, Maryland - 28 March 2022: MaxCyte, Inc. (NASDAQ:
MXCT; LSE: MXCT), a leading commercial cell-engineering company
focused on providing enabling platform technologies to advance
innovative cell-based research as well as next-generation cell
therapeutic discovery, development and commercialization ,
announces that on 25 March 2022, a total of 642,000 options of
common stock in the Company ("Common Stock") were granted to PDMRs
who are officers of the Company ("Option Grants"). Details of the
Option Grants are given below:
Option Grants to PDMRs
Doerfler, Doug 500,000
--------
Murphy, Amanda 142,000
--------
Total 642,000
--------
Option Grants vest 12/48th of the total grant one year after
date of grant, and thereafter vest 1/48(th) per month for 36 months
after the date of grant. The Option Grants have an exercise price
of $7.12 equal to the closing price of Maxcyte's stock on the
Nasdaq Stock Exchange on 25 March 2022.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Doerfler, Doug
Murhphy, Amanda
==================================================================== ===========================================
2 Reason for the notification
=================================================================================================================
a) Position/status Doerfler, Doug - CEO and Director
Murphy, Amanda - CFO
==================================================================== ===========================================
b) Initial notification/Amendment Initial notification
==================================================================== ===========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=================================================================================================================
a) Name MaxCyte, Inc.
==================================================================== ===========================================
b) LEI 54930053YHXULRFCU991
==================================================================== ===========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=================================================================================================================
a) Description of Grant of Options over Shares of Common
the financial instrument, Stock
type of instrument
==================================================================== ===========================================
b) Identification
Code
==================================================================== ===========================================
c) Nature of the transaction Grant of Options
==================================================================== ===========================================
d) Price(s) and volume(s) Doerfler, Doug - 500,000 at an exercise
price of $7.12
Murphy, Amanda - 142,000 at an exercise
price of $7.12
==================================================================== ===========================================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
==================================================================== ===========================================
f) Date of the transaction 25 March 2022
==================================================================== ===========================================
g) Place of the transaction Nasdaq Stock Exchange
==================================================================== ===========================================
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation (R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Accounting
Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBDGDXLBDDGDI
(END) Dow Jones Newswires
March 28, 2022 08:19 ET (12:19 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
